Why the study?
Calcific aortic valve disease lacks effective pharmacotherapies and the mechanism by which oscillatory shear stress-induced extracellular vesicles promote aortic valve calcification is unknown.
Does genetic ablation of circILRUN or pharmacological inhibition of NAT10 reduce aortic valve calcification in preclinical models?
Population
Human valvular endothelial cells, human valvular interstitial cells, and two independent mouse models of aortic valve calcification
Comparison
Genetic ablation of circILRUN or pharmacological inhibition of NAT10 vs control
Design
Preclinical mechanistic study
Key result
Genetic ablation of circILRUN or pharmacological inhibition of NAT10 attenuated aortic valve calcification in mouse models by disrupting the OSS-induced sEV-circILRUN-NAT10-CD36 axis.
Authors
Loading...
May identify NAT10 inhibition as a target for aortic valve calcification; hypothesis-generating in mice but leaves open human translation.
Does genetic ablation of circILRUN or pharmacological inhibition of NAT10 reduce aortic valve calcification in preclinical models?
This study identifies a novel mechanosensitive pathway (sEV-circILRUN-NAT10-CD36 axis) driving aortic valve calcification and highlights NAT10 as a potential therapeutic target.
Chen et al. (2026) studied Calcific aortic valve disease (CAVD). Genetic ablation of circILRUN or pharmacological inhibition of NAT10 was evaluated on Aortic valve calcification. Genetic ablation of circILRUN or pharmacological inhibition of NAT10 attenuated aortic valve calcification in mouse models by disrupting the OSS-induced sEV-circILRUN-NAT10-CD36 axis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: